Giovanna Palumbo

Mrs. Giovanna Palumbo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Animals
Verified
Journal Article
Open access
PDF file
GPGiovanna Palumbo
Giovanna Palumbo
LKLea Helena Kunze
Lea Helena Kunze
RORosel Oos
Rosel Oos
KWKarin Wind-Mark Wind-Mark
Karin Wind-Mark Wind-Mark
SLSimon Lindner
Simon Lindner
MBMatthias Brendel
Matthias Brendel
Longitudinal studies on mouse models related to Alzheimer disease (AD) pathology play an important role in the investigation of therapeutic targets to help pharmaceutical research in the development of new drugs and in the attempt of an early diagnosis that can contribute to improving people’s quality of life. There are several advantages to enriching longitudinal studies in AD models with Positron Emission Tomography (PET); among these advantages, the possibility of following the principle of the 3Rs of animal welfare is fundamental. In this manuscript, good daily experimental practice focusing on animal welfare is described and commented upon, based on the experience attained from studies conducted in our Nuclear Medicine department.

26 July 2024 in NeuroImage
Verified
Journal Article
Open access
JGJohannes Gnörich
Johannes Gnörich
MKMara Koehler
Mara Koehler
KWKarin Wind-Mark
Karin Wind-Mark
CKCarolin Klaus
Carolin Klaus
AZArtem Zatcepin
Artem Zatcepin
MBMatthias Brendel
Matthias Brendel
β-amyloid (Aβ) small animal PET facilitates quantification of fibrillar amyloidosis in Alzheimer's disease (AD) mouse models. Thus, the methodology is receiving growing interest as a monitoring tool in preclinical drug trials. In this regard, harmonization of data from different scanners at multiple sites would allow the establishment large collaborative cohorts and may facilitate efficacy comparison of different treatments. Therefore, we objected to determine the level of agreement of Aβ-PET quantification by a head-to-head comparison of three different state-of-the-art small animal PET scanners, which could help pave the way for future multicenter studies. Within a timeframe of 5 ± 2 weeks, transgenic APPPS1 (n=9) and wild-type (WT) (n=8) mice (age range: 13-16 months) were examined three times by Aβ-PET ([18F]florbetaben) using a Siemens Inveon DPET, a Mediso nanoScan PET/MR, and a Mediso nanoScan PET/CT with harmonized reconstruction protocols. Cortex-to-white-matter 30-60min p.i. standardized uptake value ratios (SUVRCTX/WM) were calculated to compare binding differences, effect sizes (Cohen's d) and z-score values of APPPS1 relative to WT mice. Correlation coefficients (Pearson's r) were calculated for the agreement of individual SUVR between different scanners. Voxel-wise analysis was used to determine the agreement of spatial pathology patterns. For validation of PET imaging against the histological gold standard, individual SUVR values were subject to a correlation analysis with area occupancy of methoxy-X04 staining. All three small animal PET scanners yielded comparable group differences between APPPS1 and WT mice (∆PET=20.4% ± 2.9%, ∆PET/MR=18.4% ± 4.5%, ∆PET/CT=18.1% ± 3.3%). Voxel-wise analysis confirmed a high degree of congruency of the spatial pattern (Dice coefficient (DC)PETvs.PET/MR=83.0%, DCPETvs.PET/CT=69.3%, DCPET/MRvs.PET/CT=81.9%). Differences in the group level variance of the three scanners resulted in divergent z-scores (zPET=11.5 ± 1.6; zPET/MR=5.3 ± 1.3; zPET/CT=3.4 ± 0.6) and effect sizes (dPET=8.5, dPET/MR=4.5, dPET/CT=4.1). However, correlations at the individual mouse level were still strong between scanners (rPETvs.PET/MR=0.96, rPETvs.PET/CT=0.91, rPET/MRvs.PET/CT=0.87; all p≤0.0001). Methoxy-X04 staining exhibited a significant correlation across all three PET machines combined (r=0.76, p<0.0001) but also at individual level (PET: r=0.81, p=0.026; PET/MR: r=0.89, p=0.0074; PET/CT: r=0.93, p=0.0028). Our comparison of standardized small animal Aβ-PET acquired by three different scanners substantiates the possibility of moving towards a multicentric approach in preclinical AD research. The alignment of image acquisition and analysis methods achieved good overall comparability between data sets. Nevertheless, differences in variance of sensitivity and specificity of different scanners may limit data interpretation at the individual mouse level and deserves methodological optimization.

21 March 2025 in NeuroImage
Verified
Journal Article
Open access
LKLea Helena Kunze
Lea Helena Kunze
GPGiovanna Palumbo
Giovanna Palumbo
JGJohannes Gnörich
Johannes Gnörich
KWK. Wind-Mark
K. Wind-Mark
RSR. Schaefer
R. Schaefer
MBMatthias Brendel
Matthias Brendel
Neurodegeneration, accumulation of β-amyloid (Aβ) plaques, and neuroinflammation are the major hallmarks of Alzheimer's disease. Here, we aimed to investigate the temporal and spatial association between synaptic activity, Aβ plaque load, and neuroinflammation in an Aβ mouse model with limited neurodegeneration. 26 APPSL70 and 15 C57Bl/6 mice underwent longitudinal PET-scans with [18F]UCB-H from plaque onset to levels of strong plaque load (5.3 - 11.0 months of age) to assess the synaptic vesicle protein 2A (SV2A) expression, [18F]FBB to determine the fibrillar Aβ plaque load, and [18F]GE-180 and [18F]F-DED to assess microglial and astroglial (re)activity. Statistical parametric mapping was performed to uncover similarities between the binding patterns of all four tracers. We found a continuous increase in Aβ-PET in APPSL70 mice from 5.3 to 11.0 months of age, resulting in a significantly higher [18F]FBB PET signal in the cortex, hippocampus, and thalamus of APPSL70 mice compared to C57Bl/6 mice at 11.0 months of age. Parallel increases in SV2A-PET signals were observed in the cortex and thalamus of APPSL70 mice compared to C57Bl/6 mice. Statistical parametric mapping revealed a similar pattern of Aβ- and SV2A-PET differences (dice coefficient 53%). Patterns of microglia activation showed stronger congruency with SV2A expression (dice coefficient 58%) than patterns of reactive astrogliosis (dice coefficient 26%). APPSL70 mice with limited neurodegeneration comprise a close temporal and spatial association between SV2A expression, Aβ plaque load, and microglial activation. SV2A PET imaging in APPSL70 mice may facilitate longitudinal monitoring of increased synaptic activity in the earliest phase of AD.

19 February 2026 in NeuroImage
Verified
Journal Article
Open access
IFIsabelle S. Fuxjäger
Isabelle S. Fuxjäger
MAMelissa Antons
Melissa Antons
EMEmna Marouane
Emna Marouane
GLGiulia Leschiutta
Giulia Leschiutta
RORosel Oos
Rosel Oos
AZAndreas Zwergal
Andreas Zwergal
Animal models of acute unilateral vestibulopathy are well established for the study of adaptive lesion-induced neuroplasticity, because symptoms of acute vestibular asymmetry such as nystagmus and postural imbalance recover over time as central vestibular compensation mechanisms commence action. The purpose of this study was to compare these mechanisms in a postganglionic complete unilateral vestibular neurectomy model (UVN) vs. a preganglionic incomplete chemical unilateral labyrinthectomy model (cUL) using a longitudinal [18F]FDG/[18F]UCB-H dual tracer positron emission tomography (PET) approach accompanied by multimodal behavioral testing. Twenty-four male Sprague Dawley rats underwent either cUL or UVN. Postoperatively, [18F]FDG PETs were conducted weekly for four weeks to depict changes of [18F]FDG as a surrogate for functional plasticity, and [18F]UCB-H PETs were carried out at three time points over nine weeks to visualize alterations in synaptic density indicating structural plasticity. Behavioral recovery was assessed weekly using a clinical scoring system and open field evaluation. Behavioral data reflected comparable compensation dynamics between groups. Both [18F]FDG and [18F]UCB-H PET revealed a similar spatial pattern of brain regions involved in adaptive neuroplasticity. However, while the relative extent of [18F]FDG uptake in these networks was comparable across both models, synaptic density changes were more pronounced in UVN vs. cUL. Specifically, synaptic density in the vestibular nuclei was significantly lower after UVN, accompanied by a more intense compensatory increase in sensorimotor cortical areas. In conclusion, synaptic density imaging may be a more sensitive method to depict subtle differences in mechanisms of lesion-induced adaptive neuroplasticity than traditional techniques such as imaging of glucose metabolism.

13 November 2019 in Blood
Verified
Journal Article
Open access
Fiorina GionaFiorina Giona
Fiorina Giona
CBCarlo Di Bonaventura
Carlo Di Bonaventura
PMPatrizia Mancini
Patrizia Mancini
GTGianmarco Tessari
Gianmarco Tessari
TRTurchetta Rosaria
Turchetta Rosaria
FCFrancesca CARAMIA
Francesca CARAMIA
Gaucher Disease (GD) is an autosomal recessive metabolic disorder due to glucocerebrosidase deficit. There are three main clinical phenotypes: type I (GD1: non-neuronopathic form), characterized by a visceral involvement that can mimic a hematologic disease; type II (GD2: acute neuropathic form) and type III (GD3) characterized by a slower and progressive neurological involvement. Hematologists have often involved in diagnosis and management of the GD1 patients. Increasing data and our experience show that patients with GD1 may present manifestations of Parkinson's disease or Parkinsonism symptoms (tremor, bradykinesia and rigidity), frequently combined with cognitive impairment and behavioral alterations. The aim of this study is to deeply investigate the neurological and neuropsychiatric aspects in GD1 patients in order to identify clinical and subclinical neurological manifestations, including cognitive impairment and behavioral alterations in this category of patients. This observational, monocentric, and prospective study is planned to enroll 22 GD patients (19 GD1 patients and 3 GD3 patients with or without active neurological signs) aged >12 years. Neurological assessments include: clinical evaluation including Severity Scoring Tool Unified Parkinson's Disease Rating scale and Epworth Sleepiness scale, psycho-diagnostic tests and psychiatric evaluation using cognitive test battery and two psychiatric (BPRS) and psychological (CBA 2.0) questionnaires, Somatosensory and Motors Evoked Potentials, Electroencephalography (EEG) and magnetic resonance (MR) 3Tesla, at baseline, after 12 months and 24 months. Preliminary results concerning the baseline evaluation of first cohort of patients are here reported. Since June 2019, 11 patients (10 GD1 and 1 symptomatic GD3) have been enrolled. Neurological impairment according to the major features (Gaucher severity score tool) was found in 4/11 patients: signs of Parkinson disease in 1 GD1 patient, motoneuron disease in 1 GD3 patients, abnormalities in ocular motility and psycho-cognitive disturbances in 2 GD1 patients. Minor features of a neurological impairment was found as follows: bradykinesia in 5 GD1 patients, excessive daytime sleepiness in 5 GD1 patients, and saccadic slowness in 1 GD1 patient. EEG revealed focal or diffuse slow waves in 6 patien patients (5 GD1 and 1 GD3). Cognitive and psychological evaluations revealed the presence of significant psychiatric symptoms such as depression, anxiety, and physical concerns. Six patients (5 GD1and 1 GD3) surprisingly had sensorineural hearing loss. Auditory Brainstem Response revealed abnormal disyncrony-like morphology and central speech processing in noise in 3 GD1 and in 4 (3 GD1 and 1 GD3) patients, respectively. Ophthalmological evaluation highlighted a normal visus and intraocular pressure in all patients. Moderate alterations of the fundus were present in 2 patients (1 GD1 and 1 GD3) and superficial corneal dystrophies in 3 (2 GD1 and 1 GD3) patients. An increased latency and moderate reduction in the amplitudes of optic nerve function were found in all tested patients. The retinal responses to the Electroretinogram exam were of excellent quality in all but one GD1 patient, who showed slightly reduced responses. The spectral domain-optical coherence tomography (SD-OCT) examination showed posterior pole alterations in 3 patients (2 GD1 and 1 GD3) and borderline nerve fiber layers of the optic nerve (RNFL) in 3 (2 GD1 and 1 GD3) cases. Our clinical study represents quite an innovative one, since neurological investigations are focused on GD2 and GD3 phenotypes. Neurological involvement with different phenotypical aspects were also found in GD1 patients. Sensorineural hearing loss and central alteration of auditory processing were present in higher incidence compared to the unaffected population. Psychological data din't show significant cognitive impairments, but pointed out some psychiatric aspects, such as anxiety, depression and somatic concerns. MR 3Tesla can be an important tool to better understand these data. Evaluation of the remaining cohort of patients and longer follow-up could confirm that neurological involvement is not exclusive of the type 3 GD.

8 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KWKarin Wind-Mark Wind-Mark
Karin Wind-Mark Wind-Mark
LKLea Helena Kunze
Lea Helena Kunze
MWMichael Willem
Michael Willem
GPGiovanna Palumbo
Giovanna Palumbo
CGCamilla Giudici
Camilla Giudici
AZArtem Zatcepin
Artem Zatcepin
Neuroinflammation is increasingly recognized as a key modulator of therapeutic response and adverse events in Alzheimer’s disease (AD), especially during anti-amyloid-β (Aβ) monoclonal antibody (Aβ-mAb) treatment. We applied longitudinal translocator protein (TSPO) positron emission tomography (PET) to evaluate microglial activation in response to chronic Aβ-mAb therapy and its modulation by the PPAR-γ agonist pioglitazone. AppNL-G-F knock-in mice underwent TSPO-PET and Aβ-PET imaging at 5, 7.5, and 10 months of age across four treatment arms: placebo, Aβ-mAb, pioglitazone, and combination therapy. TSPO-PET detected early and progressive neuroinflammatory responses to Aβ-mAb that were attenuated by pioglitazone co-treatment. Both mono- and combination therapy modulated the temporal and spatial dynamics of the TSPO-PET signal. In addition, we derived a microglial desynchronization index from TSPO-PET connectivity, which captured individual neuroimmune responses and correlated with cognitive performance. Together, TSPO-PET and its regional synchronicity can quantify longitudinal, region-specific treatment effects, which may help to differentiate harmful from adaptive neuroinflammatory responses. These findings highlight the potential of TSPO-PET as a stratification biomarker to optimize therapeutic interventions. In summary, TSPO-PET enables in vivo tracking of treatment-associated neuroinflammatory responses during anti-Aβ immunotherapy and provides a non-invasive framework for evaluating combination strategies targeting amyloid pathology and immune regulation in AD.